Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Effect of topographic astigmatism on refractive outcome in myopic eyes

Poster Details

First Author: A.Frings GERMANY

Co Author(s):    J. Steinberg   V. Druchkiv   T. Katz   S. Linke           

Abstract Details

Purpose:

In eyes with a preoperative plano refractive cylinder, it would appear that there is no rationale for astigmatic treatment. The aim of this retrospective, cross-sectional data analysis was to determine the amount of topographic astigmatism in refractive plano eyes that results in reduced efficacy after myopic laser in situ keratomileusis (LASIK).

Setting:

Medical University Hospital Hamburg-Eppendorf, Germany; Universitätsklinikum Erlangen, Germany

Methods:

This study included 267 eyes from 267 consecutive myopic patients with a refractive plano cylinder. Receiver operating characteristic analysis was used to find the cut-off values of preoperative topographic astigmatism that can best discriminate between groups of efficacy and safety indices in preoperative plano refractive cylinder eyes.

Results:

Preoperative topographic astigmatism of ≤0.9 diopters (D) resulted in an efficacy index of at least 0.8 statistically significantly more frequently than eyes with a preoperative ORA of >0.9 D. Eyes with a high topographic astigmatism preoperatively also had a high topographic astigmatism postoperatively. Regression analysis showed that each diopter of preoperative topographic astigmatism reduced efficacy by 0.07.

Conclusions:

A preoperative corneal astigmatism of ≥0.9 D could (partially) be taken into account in the LASIK design, even if the subjective refractive astigmatism is neutral.

Financial Disclosure:

NONE

Back to Poster listing